Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Ocular Therapeutix, Inc. (OCUL) had Revenue of $13.25M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$13.25M
Net Income	$-64.65M
Cost of Goods Sold	$1.59M
Gross Profit	$11.66M
Operating Expenses	$83.01M
Operating Income	$-69.76M
Non-Operating Income/Expense	$5.11M
Pre-Tax Income	$-64.65M
Normalized Pre-Tax Income	$-64.65M
Income after Taxes	$-64.65M
Income from Continuous Operations	$-64.65M
Consolidated Net Income/Loss	$-64.65M
Normalized Income after Taxes	$-64.65M
EBIT	$-69.76M
EBITDA	$-68.51M
Weighted-Average Shares Outstanding (Basic)	187.24M
Weighted-Average Shares Outstanding (Diluted)	187.24M
Earnings per Share (EPS) (Basic)	$-0.27
Earnings per Share (EPS) (Diluted)	$-0.27
Balance Sheet Financials
Current Assets	$782.13M
Property, Plant, and Equipment	$19.68M
Long-Term Assets	$25.93M
Total Assets	$808.06M
Current Liabilities	$50.81M
Long-Term Debt	$71.34M
Long-Term Liabilities	$102.94M
Total Liabilities	$153.75M
Common Equity	$654.31M
Tangible Shareholders Equity	$654.31M
Shareholders Equity	$654.31M
Common Shares Outstanding	215.93M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-204.88M
Cash Flow from Investing Activities	$-11.88M
Cash Flow from Financial Activities	$561.72M
Beginning Cash	$393.72M
End Cash	$738.67M
Increase/Decrease in Cash	$344.96M
Stock-Based Compensation	$43.18M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	15.39
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.10
Debt to Equity Ratio	0.11
Gross Margin	87.97%
Operating Margin	-526.50%
EBIT Margin	-526.50%
EBITDA Margin	--
Pre-Tax Profit Margin	-487.95%
Profit Margin	-487.95%
Free Cash Flow	$-216.76M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.02
Inventory Turnover	0.45
Receiveable Turnover	0.43
Days Sales in Receivables	208.19
Return on Equity	-9.88%
Return on Tangible Equity	-9.88%
Return on Assets	-8.00%
Return on Investments	-8.91%
Book Value Per Share	$3.03
Free Cash Flow per Share	$-1.16
Operating Cash Flow per Share	$-1.09

Data from Zacks Investment Research, Inc.